Tango Therapeutics (TNGX) analyst forecast and price target
Analyst forecast
Consensus of 13 analyst ratings
Based on 7 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Maintained | Buy | $68.00 from $66.00 | Aug 18, 2026 |
| Guggenheim | Maintained | Buy | $35.00 from $32.00 | Aug 12, 2026 |
| Mizuho | Maintained | Outperform | $40.00 from $36.00 | Jul 17, 2026 |
| JP Morgan | Initiated Coverage | Overweight | $46.00 | Jul 15, 2026 |
| Canaccord Genuity | Maintained | Buy | $46.00 from $42.00 | Jun 29, 2026 |
| Jefferies | Upgraded | Hold → Buy | $60.00 from $27.00 | Jun 26, 2026 |
| Canaccord Genuity | Maintained | Buy | $42.00 | Jun 11, 2026 |
| Canaccord Genuity | Maintained | Buy | $42.00 from $30.00 | Jun 9, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $66.00 from $27.00 | Jun 9, 2026 |
| Leerink Partners | Maintained | Outperform | $69.00 from $55.00 | Jun 8, 2026 |
| Piper Sandler | Downgraded | Overweight → Neutral | $24.00 from $16.00 | May 15, 2026 |
| Mizuho | Maintained | Outperform | $30.00 from $20.00 | May 15, 2026 |
| Wedbush | Maintained | Outperform | $33.00 from $19.00 | May 14, 2026 |
| Leerink Partners | Maintained | Outperform | $55.00 from $28.00 | May 14, 2026 |
| Jefferies | Downgraded | Buy → Hold | $27.00 from $18.00 | May 14, 2026 |
| Stifel | Maintained | Buy | $40.00 from $24.00 | Apr 27, 2026 |
| Canaccord Genuity | Initiated Coverage | Buy | $30.00 | Apr 2, 2026 |
| Mizuho | Maintained | Outperform | $20.00 from $19.00 | Mar 11, 2026 |
| Stifel | Maintained | Buy | $24.00 from $15.00 | Mar 9, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $27.00 from $13.00 | Mar 6, 2026 |
Frequently asked questions
What is the price target for TNGX stock?
The average 12-month analyst price target for Tango Therapeutics (TNGX) is $52.00, with a high estimate of $69.00 and a low of $35.00, across 7 analysts.
Is TNGX a buy, sell, or hold?
Analysts covering Tango Therapeutics currently average a Buy rating: 12 buy, 1 hold and 0 sell, from 13 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for TNGX?
The average price target of $52.00 implies 129.07% upside from the last price of $22.70.
What is the latest analyst rating on TNGX?
On Aug 18, 2026, HC Wainwright & Co. maintained Tango Therapeutics at Buy with a price target of $68.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.